Urticaria pigmentosa: clinical picture and response to oral disodium cromoglycate.
Fifty-six children and adults with urticaria pigmentosa were examined and their symptoms evaluated. Thirteen patients with cutaneous and systemic symptoms consented to participate in a blind trial and were treated for 1 month with placebo and for another month with oral disodium cromoglycate (DSCG). More than 66% of the patients noted relief of pruritus and gastrointestinal symptoms with DSCG. Reduction of wealing was less prominent. Patients have been continued on 400-800 mg of DSCG daily for up to 15 months with continuous improvement of their symptoms and no adverse effects.
D000328:Adult; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011537:Pruritus / Q000209:etiology; D014582:Urticaria Pigmentosa / Q000150:complications / Q000188:drug therapy*
D004205:Cromolyn Sodium